Aduhelm

The pharmaceutical firm Biogen has stopped a real-world clinical trial for its federally approved Alzheimer’s disease drug aducanumab (Aduhelm).

Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...

Patients weigh risks of taking new Alzheimer’s drug Aduhelm … Palliative care services vary by U.S. region for these groups … ​​The puzzling virus that affects almost everyone: Epstein-Barr …...

CDC reforming COVID-19 guidance … Nearly three-quarters of the U.S. now estimated to be immune to omicron variant … Brain synapse destruction culprit behind Alzheimer’s cognitive decline … Treatment...

The lawsuit alleges securities fraud on behalf of investors, adding to the ongoing fallout following Aduhelm’s controversial approval and Medicare’s questionable coverage proposal.

Higher pay not a cure-all for nurse retention, study shows … Majority of public support ongoing Aduhelm trials, would accept greater coverage costs, poll finds … 3G mobile network shutdown starts...

The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.

Nursing home visitors in Rhode Island must now be fully vaccinated or test negative for COVID … Frist named CEO at naviHealth … Medicare proposes controversial Alzheimer’s drug coverage only for...

With the 50% price drop of Aduhelm on January 1, there is good reason for CMS to reassess a hefty proposed premium hike for 2022, the U.S. health secretary said. On Wednesday, CMS is expected to announce...

U.S. Secretary of Health and Human Services Xavier Becerra on Monday ordered Medicare to reassess a big premium increase facing millions of seniors this year, after an expensive new Alzheimer’s drug...